Research Program: Cancer Immunology

项目总结：癌症免疫学（CI） 在过去的十年中，免疫疗法已经成为一种既定的模式，它正在彻底改变免疫疗法。 治疗多种癌症。癌症免疫学（CI）研究计划的重点是遗传学 操纵T细胞，应用合成生物学的新原理，并将工程化T细胞与小 分子和抗体，以扩大应用和提高安全性和有效性的过继 免疫疗法尽管免疫学方法在治疗某些恶性肿瘤方面取得了成功， 我们目前对进展中的肿瘤与肿瘤生长之间复杂关系的理解存在重大差距， 宿主免疫，这些必须被理解和克服，以实现免疫治疗的潜力， 许多常见的癌症。CI计划将侧重于系统地解决这些障碍， 肿瘤使用各种免疫学模型单独和组合。CI的具体目标是 (1)为成人和儿童恶性血液病开发有效和安全的细胞免疫疗法 和实体瘤，（2）识别和克服免疫介导的肿瘤根除的障碍， 标本和临床前模型，（3）将基础免疫学和合成生物学的发现转化为 癌症免疫治疗的新临床应用。 癌症免疫学（CI）计划目前有来自11个部门和部门的39名成员， 财团机构。19名成员在弗雷德哈奇有主要任命，12名成员在 华盛顿大学，和8名成员在西雅图儿童。14名新教师加入了这一行列 在最后一个周期中。慈善社成员目前的研究资助为2 340万美元（直接费用），用于研究 赠款资金，其中440万美元（19%）来自NCI，780万美元（33%）经过同行评审。癌症 免疫学项目在上一个资助期内共发表了470篇论文，其中14%是内部论文， 其中，49%是跨计划的，50%有外部共同作者。计划成员有 利用了所有12个联盟共享资源。这P30补助金还通过提供帮助该计划 为传播与信息会议提供行政和后勤支持，为新的研究项目提供试点资金，以及招聘 新教师的资源。

PROJECT SUMMARY: CANCER IMMUNOLOGY (CI) Over the past decade, immunotherapy has emerged as an established modality that is revolutionizing the treatment of many cancers. The Cancer Immunology (CI) Research Program has focused on genetically manipulating T cells, applying new principles of synthetic biology, and combining engineered T cells with small molecules and antibodies to broaden the applications and improve the safety and efficacy of adoptive immunotherapy. Despite the success achieved with immunologic approaches in treating some malignancies, major gaps exist in our current understanding of the complex relationship between progressing tumors and host immunity, and these must be understood and overcome to achieve the potential of immunotherapy in many common cancers. The CI program will focus on systematically tackling these barriers to eradicating tumors using a variety of immunotherapeutic modalitie alone and in combination. The specific aims of CI are (1) to develop effective and safe cellular immunotherapies for adult and pediatric hematologic malignancies and solid tumors, (2) to identify and overcome the barriers to immune-mediated tumor eradication using clinical specimens and preclinical models, (3) to translate discoveries in basic immunology and synthetic biology to novel clinical applications in cancer immunotherapy. The Cancer Immunology (CI) program currently has 39 members from 11 departments and divisions and 4 Consortium institutions. Nineteen members have primary appointments at Fred Hutch, 12 members at University of Washington, and 8 members at Seattle Children’s. Fourteen new faculty members joined this program in the last cycle. The current research support of CI members is $23.4M (direct costs) in research grant funding, of which $4.4M (19%) is from the NCI and $7.8M (33%) is peer reviewed. The Cancer Immunology program published a total of 470 papers in the last grant period, of which 14% were intra- programmatic, 49% were inter-programmatic, and 50% had external co-authors. Program members have utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing administrative and logistical support for CI meetings, pilot funding for new research projects, and recruitment resources for new faculty.